Basis: Current FMP quote-based enterprise value / four-quarter operating income. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBIT ratio is N/A as of 2026-10-06T19:08:25.691Z.
Calculation as of: 2026-10-06T19:08:25.691Z.
Quote observation: 2026-10-06T19:05:07.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 667dd3b64d3a271f66e92979ae52668ccbc7e2b5b2cdee7c8377401ac3ef4785
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBIT RATIO
N/A
Market Cap
$440.82M
EV/EBIT Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$447.00M
EV/EBIT Ratio
N/A
TTM Avg
0.21x
3Y Avg
0.21x
5Y Avg
0.21x
Market Cap
$448.83M
EV/EBIT Ratio
N/A
TTM Avg
84.81x
3Y Avg
33.20x
5Y Avg
21.83x
| NAME | MARKET CAP | EV/EBIT RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Tectonic Therapeutic, Inc. (TECX) | $437.20M | N/A | N/A | N/A | N/A |
| Assembly Biosciences, Inc. (ASMB)vs › | $439.84M | N/A | N/A | N/A | N/A |
| Capricor Therapeutics, Inc. (CAPR)vs › | $440.82M | N/A | N/A | N/A | N/A |
| NeuroPace, Inc. (NPCE)vs › | $441.17M | N/A | N/A | N/A | N/A |
| Editas Medicine, Inc. (EDIT)vs › | $429.69M | N/A | N/A | N/A | N/A |
| Ovid Therapeutics Inc. (OVID)vs › | $447.00M | N/A | 0.21x | 0.21x | 0.21x |
| Tilray Brands, Inc. (TLRY)vs › | $426.64M | N/A | N/A | N/A | N/A |
| DiaMedica Therapeutics Inc. (DMAC)vs › | $448.83M | N/A | 84.81x | 33.20x | 21.83x |
| ARS Pharmaceuticals, Inc. (SPRY)vs › | $426.13M | N/A | N/A | N/A | N/A |
| NeoGenomics, Inc. (NEO)vs › | $425.51M | N/A | 64.08x | 60.43x | 132.37x |
EV/EBIT = Enterprise Value / EBIT (TTM)
Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
